Replimune Group 3Q 2026: Revenue $0 Net loss $57.1M, EPS ($0.54) — 10-Q Summary

Replimune Group reported no revenue in Q3 2026, with net loss narrowing to $57.1M from $83.1M a year earlier. Diluted loss per share was $0.54. The FDA approved TUDRIQEV in August, with U.S. sales starting in October. Over 15 institutions began treatments by October 23. The company is conducting clinical trials for TUDRIQEV and RP2.

Original reporting
Published Oct 28, 2026, 11:31 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 11:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Replimune Group 3Q 2026: Revenue $0 Net loss $57.1M, EPS ($0.54) — 10-Q Summary — source image
Decision brief

The 30-second read

$REPLNeutralMed
01

Why it matters

Traders can update expectations for commercialization timing (revenue lag after FDA accelerated approval) and monitor upcoming confirmatory and RP2 REVEAL milestones that could affect risk perception.

02

Market read

The filing provides a concrete post-approval commercialization timeline (availability in early October) alongside financials showing no product revenue yet, informing near-term valuation and catalyst tracking.

03

What to watch

Confirmatory IGNYTE-3 enrollment of about 400 patients and the planned Phase 2/3 transition for RP2 REVEAL in 1Q 2027 may be the next major inflection points, not the current quarter’s revenue.

Relevance 7/10Novelty 6/10Timing: 10-Q filed Oct. 28, 2026, reflecting early post-approval commercialization starting in October.

Background

The article summarizes Replimune Group’s 3Q 2026 10-Q, including financial results and commercialization/clinical trial status for TUDRIQEV.

Company-level read

Ticker impact

$REPLNeutralMedium confidence
Context

Replimune Group reported 3Q 2026 revenue of $0, net loss of $57.1M, and noted TUDRIQEV commercial sales began in October after FDA accelerated approval.

Expected impact

Likely mixed reaction, with downside from $0 revenue and cash-burn optics offset by upside from FDA approval and early uptake signals.

Evidence & confidence

The filing provides both financial drag (no product revenue, large net loss) and a key regulatory/commercial milestone (accelerated approval in August, availability in early October, institutions treating patients).

Market effects

Highlights the commercialization ramp risk for oncology biotechs post-accelerated approval, where revenue may lag approval by quarters.

None material beyond US biotech investor sentiment.

Limited, focused on a single US-listed biotech and its US regulatory/commercial timeline.

Counterpoint

Early payer coverage and institution treatment counts may not translate into meaningful revenue quickly, so the $0 revenue quarter could dominate valuation.

Key entities

  • Replimune Group, Inc.

    US-listed biotech whose 3Q 2026 10-Q is summarized, including $0 product revenue and FDA accelerated approval for TUDRIQEV.

  • TUDRIQEV

    Oncology therapy that received FDA accelerated approval in August 2026 and began US commercial availability in early October.

  • IGNYTE-3

    Confirmatory trial enrolling about 400 patients, with continued enrollment referenced in the filing summary.

  • RP2 REVEAL

    Phase 2/3 transition expected in first quarter of 2027, with preliminary findings in liver and biliary cancers expected then.

Related articles

$REPLHigh

Replimune Soars 17% as TUDRIQEV Melanoma Launch Draws “Enthusiastic” Response From Physicians

Replimune (REPL) shares rose 17% after reporting strong initial uptake of TUDRIQEV, its melanoma treatment, with over 15 institutions prescribing it in three weeks. The company has $307.8 million in cash. TUDRIQEV is used with Bristol Myers Squibb's (BMY) Opdivo and targets tumors not treated by Amgen's (AMGN) Imlygic. Analysts expect revenue growth, but no sales figures are available yet.

$REPLMed

Replimune (REPL) Q2 2027 Earnings Call Transcript

Replimune (REPL) reported Q2 2027 earnings, highlighting the commercial launch of TUDRIQEV. The company noted strong physician interest and rapid adoption, with over 15 institutions prescribing the drug in less than 20 business days. Replimune reported a net loss of $57.1 million for the quarter, with $307.8 million in cash reserves. The company expects to report first product revenue in Q3 2027.

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

$REPLMed

Replimune Reports Fiscal Q2 2027 Results, $57.1 Million Net Loss

Replimune reported a net loss of $57.1M for Q2 2027, down from $83.1M a year earlier. Cash reserves were $307.8M. R&D and operating expenses decreased. TUDRIQEV, for advanced melanoma, launched commercially in the U.S. in October, with over 15 institutions prescribing it. The company is engaging with priority accounts and advancing clinical trials.

$REPLMed

Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update

Replimune Group, Inc. (REPL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update TUDRIQEV first delivered to patients for advanced melanoma on October 6th More than 15 institutions have prescribed TUDRIQEV Management will host a webcast today at 8:00 a.m.